As of close of business last night, Avenue Therapeutics Inc’s stock clocked out at $0.12, down -7.75% from its previous closing price of $0.14. On the day, 2308488 shares were traded.
Ratios:
To gain a deeper understanding of ATXI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 11 ’23 when Davidow Robert L sold 353,000 shares for $0.14 per share. The transaction valued at 49,600 led to the insider holds 22,000 shares of the business.
Davidow Robert L sold 264,000 shares of ATXI for $36,960 on Dec 11 ’23. The 10% Owner now owns 681,000 shares after completing the transaction at $0.14 per share. On Sep 08 ’23, another insider, Fortress Biotech, Inc., who serves as the 10% Owner of the company, bought 418,410 shares for $0.72 each. As a result, the insider paid 301,255 and bolstered with 1,032,390 shares of the company.
Stock Price History:
Over the past 52 weeks, ATXI has reached a high of $1.28, while it has fallen to a 52-week low of $0.11.
Shares Statistics:
A total of 44.26M shares are outstanding, with a floating share count of 39.43M. Insiders hold about 10.92% of the company’s shares, while institutions hold 2.79% stake in the company.
Earnings Estimates
As of right now, ATAI Life Sciences N.V. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $51.09, with high estimates of $0.12 and low estimates of $3.21.
Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Industrials.
